When did ULTRAGENYX PHARMACEUTICAL IN (RARE) report earnings last quarter?
ULTRAGENYX PHARMACEUTICAL IN (RARE) last reported earnings on 2/12/2026.
ULTRAGENYX PHARMACEUTICAL IN (RARE) Earnings History & Surprises
NASDAQ:RARE • US90400D1081
Current stock price
22.45 USD
+1.03 (+4.81%)
At close:
22.45 USD
0 (0%)
After Hours:
RARE Earnings overview
Past quarterly earnings results for ULTRAGENYX PHARMACEUTICAL IN (RARE), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$1.51
- Revenue Estimate
- 166.82M
Last Reported
Most Recent- Release Date
- Feb 12, 2026
- Period
- Q4 / 2025
- EPS Reported
- -$1.29
- EPS Surprise
- -15.82%
- Revenue Surprise
- 3.03%
Beat Rate
Last 8 Quarters 56%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -1.29 | -1.11 | -15.82% | 7.19% | 207M | 200.91M | 3.03% | 25.55% |
| Q3 2025 | -1.81 | -1.26 | -43.75% | -29.29% | 159.933M | 170.04M | -5.94% | 14.65% |
| Q2 2025 | -1.17 | -1.32 | 11.68% | 23.03% | 166.496M | 164.82M | 1.02% | 13.24% |
| Q1 2025 | -1.57 | -1.65 | 4.60% | 22.66% | 139.292M | 146.7M | -5.05% | 27.99% |
| Q4 2024 | -1.39 | -1.32 | -5.63% | 8.55% | 164.877M | 158.5M | 4.02% | 29.42% |
| Q3 2024 | -1.40 | -1.48 | 5.37% | 37.22% | 139.494M | 138.51M | 0.71% | 42.27% |
| Q2 2024 | -1.52 | -1.73 | 12.01% | 32.44% | 147.026M | 125.64M | 17.02% | 35.75% |
| Q1 2024 | -2.03 | -1.77 | -14.94% | 12.88% | 108.833M | 118.33M | -8.03% | 8.30% |
| Q4 2023 | -1.52 | -1.65 | 7.99% | 29.63% | 127.392M | 121.77M | 4.62% | 23.32% |
| Q3 2023 | -2.23 | -2.12 | -5.20% | 36.29% | 98.052M | 111.82M | -12.31% | 8.11% |
| Q2 2023 | -2.25 | -2.12 | -6.35% | 0.44% | 108.309M | 106.9M | 1.32% | 21.29% |
| Q1 2023 | -2.33 | -2.02 | -15.58% | -6.39% | 100.496M | 106.78M | -5.88% | 25.78% |
| Q4 2022 | -2.16 | -2.18 | 1.14% | -20.67% | 103.3M | 107.22M | -3.66% | 23.86% |
| Q3 2022 | -3.50 | -1.85 | -89.21% | -224.07% | 90.7M | 98.121M | -7.56% | 11.15% |
| Q2 2022 | -2.26 | -1.79 | -26.47% | -24.86% | 89.3M | 89.265M | 0.04% | 2.64% |
| Q1 2022 | -2.19 | -1.80 | -21.97% | -7.88% | 79.9M | 85.327M | -6.36% | -19.62% |
| Q4 2021 | -1.79 | -1.37 | -30.74% | -383.78% | 83.4M | 85.471M | -2.42% | -8.85% |
| Q3 2021 | -1.08 | -1.44 | 24.80% | 4.42% | 81.6M | 83.178M | -1.90% | 0.12% |
| Q2 2021 | -1.81 | -1.36 | -33.07% | -541.46% | 87M | 87.6M | -0.68% | 41.00% |
| Q1 2021 | -2.03 | -1.26 | -60.89% | -6.28% | 99.4M | 78.58M | 26.50% | 173.83% |
| Q4 2020 | -0.37 | -1.18 | 68.76% | - | 91.5M | 71.955M | 27.16% | - |
| Q3 2020 | -1.13 | -1.28 | 11.98% | - | 81.5M | 56.107M | 45.26% | - |
| Q2 2020 | 0.41 | -1.57 | 126.03% | - | 61.7M | 39.901M | 54.63% | - |
| Q1 2020 | -1.91 | -1.72 | -11.34% | - | 36.3M | 37.477M | -3.14% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
-10.82%
Max EPS beat (4)
11.68%
Min EPS beat (4)
-43.75%
Revenue beat statistics
Revenue beat (4)
2
Average Revenue beat (4)
-1.74%
Max Revenue beat (4)
3.03%
Min Revenue beat (4)
-5.94%
Analysis
In the last 4 quarters, RARE has beaten EPS estimates in 2 out of 4 releases
RARE has beaten revenue estimates in 2 out of the last 4 releases
In the last 4 quarters, RARE reported -10.8% below the EPS estimates on average.
In the last 4 quarters, RARE reported -1.7% below the revenue estimates on average.
Related analysis
ULTRAGENYX PHARMACEUTICAL IN / RARE Earnings FAQ
Can you provide information on whether ULTRAGENYX PHARMACEUTICAL IN beat earnings estimates in the last quarter?
ULTRAGENYX PHARMACEUTICAL IN (RARE) missed EPS estimates and beat revenue estimates in the most recent quarter.
Can you provide information on how often ULTRAGENYX PHARMACEUTICAL IN beats earnings estimates?
In the last 4 quarters, ULTRAGENYX PHARMACEUTICAL IN (RARE) has beaten EPS estimates in 2 out of 4 releases.